Robert Califf, the nominee to serve as the next FDA commissioner, and other FDA leaders called for a broad plan to reassess the agency's approach to prescription opioid medications. The move comes as Senators block a vote on his confirmation for the top post.
FDA granted accelerated approval to a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
An analysis of a previously published phase III study prospectively validated five prognostic factors, referred to as the Moore criteria, used to identify a subset of patients with advanced cervical cancer that may not benefit from bevacizumab treatment.
A phase III study comparing Vectibix (panitumumab) and best supportive care met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer.
One of the largest randomized trials ever has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20 percent after follow up of up to 14 years, but researchers say longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective.
Researchers conducted a large analysis of breast cancer cell function, saying the results suggest dozens of new uses for existing drugs, new drug discovery targets, and new drug combinations.
Array BioPharma reported top-line results from the ongoing phase III clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, demonstrating that the study met its primary endpoint of improving progression-free survival when compared with dacarbazine treatment.
The Patient-Centered Outcomes Research Institute approved $70 million for nine new patient-centered research projects focused on conditions including ductal carcinoma in situ, diabetes, chronic lung disease and migraines.
MD ANDERSON CANCER CENTER and AbbVie formed a three-year collaboration to perform preclinical and clinical studies evaluating immuno-oncology therapies. AbbVie and MD Anderson will each assign two scientists to a joint scientific committee, which will decide on which projects to pursue. The collaboration will begin with projects driven by AbbVie Biotherapeutics. Future projects will draw... […]
